Smart Wound Dressing Releases Antibiotics - EMJ

This site is intended for healthcare professionals

Novel Wound Dressing Delivers Antibiotics on Demand

SMART wound dressing technology that releases antibiotics only when harmful bacteria are detected has shown promising results, accelerating healing and limiting resistance in preclinical models, offering a targeted approach to managing infected wounds more effectively in early studies conducted recently. 

Background And Clinical Need for Wound Dressing Innovation

Wound infections remain a major clinical challenge, with rising antimicrobial resistance undermining standard treatments. The need for advanced wound dressing solutions has intensified as β-lactamase-producing bacteria increasingly drive persistent infections. Traditional antibiotic delivery often exposes tissue to suboptimal drug levels, encouraging resistance and recurrence. Hydrogels have emerged as versatile platforms for localised therapy, enabling controlled drug release and improved healing environments. This study explores a responsive wound dressing designed to release antibiotics only when infection-specific enzymes are present. 

Enzyme Responsive Design Shows Strong Results in Models

Researchers developed a hydrogel incorporating a cephalosporin-derived β-lactamase cleavable crosslinker that degrades in the presence of bacterial enzymes, triggering release of ciprofloxacin-loaded liposomes. In ex vivo and in vivo models of Pseudomonas aeruginosa wound infections, the system demonstrated selective activation. In a murine skin abrasion infection model, a single application achieved complete bacterial eradication and enhanced wound healing, outperforming a commercial silver-based hydrogel wound dressing. Notably, the material did not induce ciprofloxacin resistance in non-β-lactamase-producing bacteria. 

Implications For Practice and Future Wound Dressing Development

These findings highlight the potential of enzyme-responsive wound dressing systems to deliver antibiotics precisely at infection sites, reducing unnecessary exposure and limiting resistance development. Such targeted delivery could improve clinical outcomes, particularly in chronic or difficult-to-treat wounds where bacterial burden fluctuates.  If validated clinically, this approach may redefine infection management by aligning antimicrobial therapy with real-time bacterial activity, supporting more sustainable and effective wound care strategies. Further evaluation of safety profiles and long-term resistance patterns will be essential before widespread clinical adoption. 

Reference 

Abbasi A et al. Bacterial enzyme-responsive hydrogels for triggered delivery of antibiotics to infected wounds. Science Advances. 2026;12(12):eadz0786. 

Featured image: Vancouver on Adobe Stock 

Author:

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.